Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Geptanolimab by Apollomics for Non-Small Cell Lung Cancer: Likelihood of Approval
Geptanolimab is under clinical development by Apollomics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
Vebreltinib DR by Apollomics for Non-Small Cell Lung Cancer: Likelihood of Approval
Vebreltinib DR is under clinical development by Apollomics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Vebreltinib DR by Apollomics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Vebreltinib DR is under clinical development by Apollomics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...
Vebreltinib DR by Apollomics for Head And Neck Cancer: Likelihood of Approval
Vebreltinib DR is under clinical development by Apollomics and currently in Phase II for Head And Neck Cancer. According to...
Benmelstobart by Apollomics for Small-Cell Lung Cancer: Likelihood of Approval
Benmelstobart is under clinical development by Apollomics and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...